TELO vs UNH

Telomir Pharmaceuticals remains an extremely high-risk, high-reward early-stage clinical biotech. Its TLM-201 asset targets vast markets (age-related diseases, cancer) with substantial long-term TAM if successful. The primary upside driver is significant clinical trial success, which remains speculative. For FY2025, the company reported an improved net loss of $10.41 million (vs. $16.53 million pr...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...